Stoke Therapeutics, Inc.
STOK
$31.16
-$1.34-4.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -144.30% | -452.70% | -45.09% | 8.61% | 527.99% |
| Total Depreciation and Amortization | -7.97% | -23.00% | -18.15% | -18.61% | -15.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.18% | 45.55% | 15.18% | 13.47% | 15.53% |
| Change in Net Operating Assets | -272.34% | 184.13% | 65.49% | -36,976.67% | 347.56% |
| Cash from Operations | -145.96% | -31.31% | -40.49% | -45.46% | 636.62% |
| Capital Expenditure | -132.24% | -452.38% | -28.16% | -234.78% | -1,166.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 270.34% | -7,164.92% | 130.86% | -68.11% | 37.84% |
| Cash from Investing | 271.88% | -7,555.56% | 130.31% | -68.19% | 36.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6,037.34% | 16,157.22% | -61.76% | -99.54% | -19.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,037.34% | 16,157.22% | -61.76% | -99.54% | -19.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -49.30% | 103.79% | 58.23% | -1,263.78% | 1,241.69% |